S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843708.43092.96 |
| _version_ | 1827336950907928576 |
|---|---|
| author | L. Vinti S. Daw C. Sabado Alvarez F. Fagioli A. Beishuizen G. Michel M. L. Moleti M. Cepelova A. Thorwarth C. Rigaud D. Plaza Lopez de Sabando J. Landman Parker Y. Zhu P. Pillai A. Nahar C. Mauz-Koerholz |
| author_facet | L. Vinti S. Daw C. Sabado Alvarez F. Fagioli A. Beishuizen G. Michel M. L. Moleti M. Cepelova A. Thorwarth C. Rigaud D. Plaza Lopez de Sabando J. Landman Parker Y. Zhu P. Pillai A. Nahar C. Mauz-Koerholz |
| author_sort | L. Vinti |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:52Z |
| format | Article |
| id | doaj.art-b8e46a274f3048e8826cebc672ef2127 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:52Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-b8e46a274f3048e8826cebc672ef21272024-03-02T03:51:40ZengWileyHemaSphere2572-92412022-06-01610510610.1097/01.HS9.0000843708.43092.96202206003-00105S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDYL. Vinti0S. Daw1C. Sabado Alvarez2F. Fagioli3A. Beishuizen4G. Michel5M. L. Moleti6M. Cepelova7A. Thorwarth8C. Rigaud9D. Plaza Lopez de Sabando10J. Landman Parker11Y. Zhu12P. Pillai13A. Nahar14C. Mauz-Koerholz151 IRCCS Ospedale Pediatrico Bambino, Gesu, Italy2 University College London Hospitals NHS Foundation Trust, London, United Kingdom3 Hospital Universitari Vall d Hebron, Barcelona, Spain4 Ospedale Infantile Regina Margherita, Turin, Italy5 Princess Máxima Centrum, Utrecht, Netherlands6 CHU de Marseille Hopital de la Timone Enfants, Marseille, France7 Universita degli Studi di Roma La Sapienza, Rome, Italy8 Fakultni nemocnice v Motole, Prague, Czechia9 Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum, Berlin, Germany10 Gustave Roussy Cancer Campus, Villejuif, France11 Hospital Universitario La Paz, Madrid, Spain12 Hopital d’Enfants Armand Trousseau, Paris, France13 Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, United States of America13 Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, United States of America13 Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, United States of America14 Justus-Liebig University of Giessen, Giessenhttp://journals.lww.com/10.1097/01.HS9.0000843708.43092.96 |
| spellingShingle | L. Vinti S. Daw C. Sabado Alvarez F. Fagioli A. Beishuizen G. Michel M. L. Moleti M. Cepelova A. Thorwarth C. Rigaud D. Plaza Lopez de Sabando J. Landman Parker Y. Zhu P. Pillai A. Nahar C. Mauz-Koerholz S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY HemaSphere |
| title | S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY |
| title_full | S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY |
| title_fullStr | S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY |
| title_full_unstemmed | S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY |
| title_short | S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY |
| title_sort | s204 pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma with slow early response to frontline chemotherapy the phase 2 open label keynote 667 study |
| url | http://journals.lww.com/10.1097/01.HS9.0000843708.43092.96 |
| work_keys_str_mv | AT lvinti s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT sdaw s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT csabadoalvarez s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT ffagioli s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT abeishuizen s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT gmichel s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT mlmoleti s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT mcepelova s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT athorwarth s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT crigaud s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT dplazalopezdesabando s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT jlandmanparker s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT yzhu s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT ppillai s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT anahar s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study AT cmauzkoerholz s204pembrolizumabinchildrenandyoungadultswithnewlydiagnosedclassicalhodgkinlymphomawithslowearlyresponsetofrontlinechemotherapythephase2openlabelkeynote667study |